Condition: Heart Failure With Reduced Ejection Fraction · Cardiogenic Shock · Sponsor: Min-Seok Kim
This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.
This description comes directly from the study's public registry record.
Min-Seok Kim, PhD · 82-2-3010-3948 · msk@amc.seoul.kr
Ah-Ram Kim, MD · 82-2-3010-0111 · ahram3256@amc.seoul.kr
Always discuss trial participation with your own doctor first.
| Asan Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06078436